Loading...
XHKG2348
Market cap232mUSD
Dec 24, Last price  
1.20HKD
1D
-0.83%
1Q
7.14%
Jan 2017
-48.50%
Name

Dawnrays Pharmaceutical (Holdings) Ltd

Chart & Performance

D1W1MN
XHKG:2348 chart
P/E
5.20
P/S
1.47
EPS
0.22
Div Yield, %
6.50%
Shrs. gr., 5y
-1.08%
Rev. gr., 5y
3.94%
Revenues
1.15b
-9.90%
584,758,000734,002,000788,797,000919,945,000947,710,0001,082,110,0001,286,683,0001,081,044,000856,539,000914,973,000783,803,000985,000,000824,351,000882,483,000948,938,000950,007,0001,024,270,0001,165,155,0001,277,682,0001,151,145,000
Net income
326m
-8.95%
80,171,000105,704,00065,878,000101,157,000102,037,000118,388,000166,840,000146,307,000114,506,000153,099,000205,145,000302,198,000265,917,000292,978,000303,960,000255,430,000268,130,000358,175,000358,057,000326,000,000
CFO
338m
-22.08%
73,740,00034,489,00050,613,000130,551,00097,799,000138,987,000252,344,00082,986,000203,624,000231,262,000377,798,000298,322,000320,258,000390,741,000274,294,000275,837,000302,903,000393,139,000434,266,000338,400,000
Dividend
Sep 16, 20240.015 HKD/sh
Earnings
May 23, 2025

Profile

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.
URL
https://www.dawnrays.com/
IPO date
Jul 11, 2003
Employees
1,132
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,151,145
-9.90%
1,277,682
9.66%
1,165,155
13.75%
Cost of revenue
860,689
855,273
783,258
Unusual Expense (Income)
NOPBT
290,456
422,409
381,897
NOPBT Margin
25.23%
33.06%
32.78%
Operating Taxes
91,390
82,557
85,160
Tax Rate
31.46%
19.54%
22.30%
NOPAT
199,066
339,852
296,737
Net income
326,000
-8.95%
358,057
-0.03%
358,175
33.58%
Dividends
(117,078)
(99,543)
(143,912)
Dividend yield
7.42%
4.98%
5.71%
Proceeds from repurchase of equity
1,172
439
(13,341)
BB yield
-0.07%
-0.02%
0.53%
Debt
Debt current
120,424
7,968
21,993
Long-term debt
570
2,422
4,034
Deferred revenue
300
600
Other long-term liabilities
175,595
Net debt
(804,832)
(1,096,791)
(891,447)
Cash flow
Cash from operating activities
338,400
434,266
393,139
CAPEX
(199,553)
(204,365)
(313,067)
Cash from investing activities
(387,573)
(175,013)
(284,202)
Cash from financing activities
2,070
(92,701)
(129,754)
FCF
121,099
395,754
30,643
Balance
Cash
1,066,697
1,081,836
830,224
Long term investments
(140,871)
25,345
87,250
Excess cash
868,269
1,043,297
859,216
Stockholders' equity
2,254,649
2,546,781
2,295,165
Invested Capital
2,111,492
1,606,632
1,711,462
ROIC
10.71%
20.48%
19.51%
ROCE
9.45%
15.42%
14.48%
EV
Common stock shares outstanding
1,502,602
1,502,310
1,507,880
Price
1.05
-21.05%
1.33
-20.36%
1.67
21.01%
Market cap
1,577,732
-21.04%
1,998,072
-20.65%
2,518,160
18.07%
EV
777,478
909,192
1,643,860
EBITDA
374,349
486,799
438,258
EV/EBITDA
2.08
1.87
3.75
Interest
989
371
641
Interest/NOPBT
0.34%
0.09%
0.17%